stocknshares BlueAllele, a Minnesota-based developer of gene editing technology, has filed a lawsuit against Intellia Therapeutics ( NASDAQ: NTLA ) in a federal court in Delaware alleging that Intellia has infringed upon three of its patents for its bio-directional insertion template technology. BlueAllele said in a statement that Intellia has used its patented platform technology to advance both internal and collaboration programs. According to Bloomberg , the suit encompasses being done through Intellia’s $100M collaboration with Regeneron ( REGN ).
Bloomberg said Intellia did not immediately respond to a request for comment. Intellia and Regeneron expanded their collaboration in October to include CRISPR-based gene edited therapies for neurological and muscular diseases. The companies have also been working on therapies to treat ATTR and hemophilia, according to Intellia’s website.
More on Intellia Therapeutics Intellia Therapeutics Presents Promising In Vivo CRISPR Results Intellia Therapeutics: 3 Near-Term Pivotal In Vivo Gene Therapies Intellia Therapeutics, Inc. (NTLA) Q1 2024 Earnings Call Transcript Intellia rallies on Phase 1 data for CRISPR-based HAE therapy Intellia Therapeutics Q1 2024 Earnings Preview.
